SEO URLwww.firestrike.ai/deals/avidity-biosciences-novartis-acquisition-2026-3
acquisitionAnnounced · Jan 13, 2026HealthcareSource · MagazinesArticle · Factual
Novartis acquires Avidity Biosciences
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
—
Target
Avidity Biosciences
NASDAQ: RNA · San Diego, California
Acquirer
Novartis
Full Acquisition
Status
Pending
Novartis agreed to acquire Avidity Biosciences. Reported deal value: Undisclosed. Status: Pending. Sector: Healthcare. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-13. Figures and status may change as filings and press coverage update.
Last year, Novartis agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as it looks to bolster its portfolio of treatments for rare muscle disorders
Deal timeline
Announced
Jan 13, 2026 · globalbankingandfinance.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Healthcare. Figures and status may change as sources update.
Sources: globalbankingandfinance.com · Primary article · FireStrike proprietary index